GI Flashcards
Bevacizumab
An anti-VEGF-A humanized monoclonal antibody which serves to reverse the “leakiness” induced by VEGF. This “leakiness” prevents adequate drug delivery to tumors. It traps VEGF so that it can’t interact with VEGFR-2 receptor
When combined with carboplatin and paclitaxel increases survival in non-small cell lung cancer by 2 months (also for colorectal cancer, renal cell carcinoma)
Given IV
Contraindicated in patients with a history of hemoptysis, brain metastasis, or a bleeding diathesis. It also makes surgery more risky, and can cause severe hypertension and proteinuria. Can occosionally cause strokes, MIs, and gastric perforation. Risk of colonic perforation increasees with intact primary colonic tumors, peritoneal carcinomatosis, PUD, diverticulitis, or prior radiation treatment. Less infusion reactions. CNS hemorrhage
Contraindicated in patients with squamous cell tumors due to unacceptably high rates of life-threatening hemoptysis in early phase clinical trials
Erlotinib
HER1/EGFR tyrosine kinase Inhibitor
Binds to the ATP binding site of kinase domain and reversibly blocks enzymatic funtion of EGFR, killing EGFR cell lines (does not block binding of EGF)
Monitor warfarin (INR) while on these drugs
Orally administered (should not be taken with food).
First-line treatment of locally advanced or metastatic pancreatic cancer in combination with gemcitabine (Thomas says colon cancer though). Approved for second-line treatment of patients with locally advanced or metastatic non-small cell lung cancer. Side effects similar to Gefitinib, along with hepatic toxicity
Side effects: diarrhea, acneform rash, anorexia, fatigue, serious or fatal interstitial lung disease, and Steven Johnson syndrome
Resistance: secondary mutations that change binding site. Amplification of met oncogene which amplifies downstream of EGFR, also KRAS mutations.
Cetuximab
Monoclonal chimeric (mouse/human) antibody that binds to the extra-cellular surface of EGFR to block receptor dimerization.
Also: antibody dependent cellular cytotoxicity (panitumumab does not have this mechanism)
Given IV
Used for squamous cell carcinomas of the head and neck (along with cisplatin based chemotherapy), metastatic colon cancer (used in patients who cannot tolerate irinotecan-based therapy, or on top of irinotecan-based therapy)
Side effects: infusion reactions: acneform rash in majority of patients, along with pruritis, nail changes, headache and diarrhea. May cause anaphylactoid reactions during infusion, especially among patients in southern US.
Panitumumab
Recombinant, fully humanized IgG against the extracellular EGFR domain.
Unlike cetuximab, it does not mediate antibody dependent cell-mediated cytotoxicity
Used in metastatic colon cancer
Leads to rash, infusion reactions, pulmonary fibrosis, and electrolyte abnormalities (same as cetuximab)
Irinotecan
Targets topoisomerase I
Converted to active form SN-38 by carboxylesterases in the liver.
Has a longer half-life than topotecan, but hepatic metabolism is significant (through glucuronidation).
Dose limiting toxicity is delayed diarrhea (polymorphism for UDG glucoronidation)(treat with loperamide). The second most common toxicity is myelosuppression. Can also lead to an anticholinergic syndrome with diarrhea, hypersalivation, lacrimation, et c.
No longer used to treat non-small cell lung cancer due to difficulty in achieving proper blood levels.
Usually used in combination with 5-FU and Leucovorin to treat late stage colon cancer. Cells can gain resistance by shifting to topoisomerase II reaction
5-Fluorouracil
A pyrimidine analog that inhibits RNA and DNA function.
Used against metastatic colon carcinomas, upper GI tract carcinomas, and breast carcinomas, but rarely used as a single agent.
Usually given IV
Used in combination with cisplatin for HNSCC, irinotecan or oxaliplatin in colon cancer. Also serves to sensitize neoplastic cells for radiation therapy
5-FU can be used in combination with methotrexate. It directly inhibits thymidylate synthase. It can also be given with leucovorin, which binds to thymidilate synthase as well to facilitate inhibition. It can also inhibit RNA processing and be incorporated into DNA
Its dose limiting toxicity is leukopenia. It can lead to mucosal ulcerations throughout the GI tract and lead to fulminant diarrhea, shock and death
Combinations: Leucovorin can be a cofactor for thimidylate synthase almost always given together
Methotrexate: inhibits purine synthesis and gathers more PRPP so 5-FU anabolism enhanced
Capecitabine
An orally administered pro-drug of 5-FU approved for the treatment of metastatic breast cancer and metastatic colorectal cancer
Causes similar toxicities as 5-FU, but with more hand-foot syndrome (erythema, desquamation, pain, and sensitivity to touch of the palms and soles), mucositis, myelosuppression
Has a polar group that provides water solubility (the sugar), a lipophilic group that allows absorption through the gut, and is stable in stomach acid. This is why it is a good oral agent
Streptozotocin
An antibiotic that is broken down to an alkylating intermediate, 2-chloroethyl diazonium, capable of alklating guanine, cytidine, and adenine bases and causing inter- and intra-strand cross-links. Better than other nitrosourea containing anti-cancers, doesn’t form a carbamoylating agent
Used in treatmnet of human pancreatic islet cell carcinoma (has a glucose attached that attracts it to islets) and malignant carcinoid tumors (often occur in small intestine, stomach).
Nausea, mild renal/hepatotoxicity occurs in two-thirds of patients (do not give with other nephrotoxic drugs). Can also cause anemia, leukopenia, or thrombocytopenia.
Resistance can be due to MGMT repair enzymes
Like most alkylating agents, it is dependent on an intact apoptotic response (p53).
Mitomycin
An antibiotic that is curative in treating anal cancers (in combination with cisplatin and 5-FU) and via direct instillation to treat superficial bladder carcinomas.
It serves as a bi- or trifunctional alkylating agent.
Given IV
Major toxicity is myelosuppression along with nausea, vomiting, diarrhea, stomatitis, rash, fever, and malaise. HUS can also occur. It can also lead to renal failure and interstitial pulmonary fibrosis, and potentiate the cardiac toxicity of doxorubicin when used in combination
Resistance is through deficient activation and P-glycoprotein mediated efflux
Doxorubicin
Anthracycline
Intercalater of DNA, Topo II inhibitior, free radical generator.
Used to treat Kaposi sarcoma, ovarian cancer, multiple myeloma, and malignant lymphomas
Can be given with an iron chelator to prevent as much free radical formation to protect against dilated cardiomyopathy.
p53 or caspase dependent
Resistance: mdr-1, decreased activity/mutated Topo II, enhanced ability to repair strand breaks
Given IV (if you miss the vein, it causes severe local vesicant action and tissue necrosis), does not cross the BBB
Can turn urine red
Myelosuppression is dose limiting toxicity, along with ST- and T-wave alterations and dilated cardiomyopathy
Epirubicin
Anthracycline indicated for treatment of breast cancer and gastric carcinoma
Same side effect profile as doxorubicin
Paclitaxel and Docetaxel
Taxanes (docetaxel is synthetic congener of pacitaxel)
Central components of regimens for treating metastatic esophageal, ovarian, breast, lung, GI, genitourinary, and head and neck cancers
albumin-bound nanoparticle solutions that bind to a different B-tubulin site as the vinca alkaloids and inhibit disassembly of microtublues (very limited water solubility, but docetaxel is more soluble)
Resistance: mdr-1, B-tubulin mutations, an increase in survivin, alpha aurora kinase.
Does not depend on p53
Dose limiting toxicity of paclitaxel is neutropenia (treat with filgrastim). Also causes hypersensivity reactions (avoid by pre-treating with dexamethasone, diphenhydramine) and peripheral neuropathy
Docetaxel causes more neutropenia but less neuropathy. Fluid retention is a problem here (treat with dexamethasone)
Vinorelbine
Microtubule binding vinca alkaloid (like vincristine)
Administered in normal saline IV. Used with cisplatin for treatment of small cell lung cancer.
Primary toxicity is granulocytopenia (with less neurotoxicity as other vinca alkaloids)
An oral formulation is active in small cell carcinoma
Cisplatin
Cisplatin penetrates CNS poorly, most is covalently bound to plasma proteins (in contrast to carboplatin).
It is inactivated by aluminum, so must avoid contact with aluminum needles.
Side effects: can cause nephrotoxicity if not treated with chloride diuresis. Causes ototoxicity that is not helped by chloride treatment (more pronounced in children). Nausea and vomitting occur in almost all patients. Also causes myelosuppression, peripheral motor and sensory neuropathy.
Associated with development of AML
Often used following surgical resection of Stage I and II non-small cell lung cancer. It produces responses against cancers of the head and neck, anal and rectal carcinomas, and sensitizes cells to radiation (especially with HNSCC)
Oxaliplatin
A platinum cooordination complex that is used against colorectal and gastric cancer. Leaving group is an oxalate instead of a chloride, like in cisplatin
MOA: exhibits a cytotoxicity that does not depend on the MMR system or the HMG proteins that are required by other platinum containing compounds, which may explain its greater role in colorectal cancer. It also supresses expression of thymidylate synthase, and is therefore often used with 5-FU (synergy), which actually up-regulates TS expression.
Dose limiting toxicity is peripheral neuropathy. An acute form is triggered by cold liquids, while a chronic form is more dose related
Overexpression of glutathione and NER mechanism can lead to resistance
Gemcitabine
Pyrimidine Analog
Inhibits DNA synthesis by inhibition of DNA polymerase and ribonucleotide reductase, cell cycle-specific for the S-phase of the cycle (also blocks cellular progression at G1/S-phase). It can also hit non-proliferating cells via inducing apoptosis
Gemcitabine is phosphorylated intracellularly by deoxycytidine kinase to gemcitabine monophosphate, which is further phosphorylated to active metabolites gemcitabine diphosphate and gemcitabine triphosphate. Gemcitabine diphosphate inhibits DNA synthesis by inhibiting ribonucleotide reductase; gemcitabine triphosphate incorporates into DNA and inhibits DNA polymerase (chain terminator).
Used against rapidly dividing and non-dividing cells
Can be used to treat non-small cell lung, metastatic pancreatic (best if tumors express hENT and low expression of RNR), ovarian, esophageal, and bladder cancer.
Activity greatly enhanced by combination with cisplatin/carboplatin
Myelosuppression is generally the dose-limiting toxicity, can cause HUS, can’t use with radiation therapy
Resistance is through increased deactivation by deoxycytidine deaminase or decreased activation by deoxycytidine kinase
GI tract acidity/ treatment of peptic ulcers
Through muscarrinic blockade, gastric secretion is blocked: volume and amount of acid, pepsin, mucin are all reduced
Pirenzepine: muscarinic antagonist, like atropine, reduces gastric acid secretion but with fewer side effects.
Telenzepine: similar to pirenzepine except it is more potent analog
These drugs are investigational in the US
Drugs used in acid-peptic diseases: diseases include GERD, peptic ulcer, stress-related mucosal injury. All of these involve erosion or ulceration due to acid, pepsin, bile overwhelming the defensive barriers of the GI mucosa (mucus, bicarb, PGE2, blood flow)
Antacids
Treatment of dyspepsia and acid-peptic disorders
Weak bases that react with HCL forming salt and water
Sodium Bicarbonate (baking soda, alka seltzer): reacts with HCL to form CO2 and NaCl, resulting in gastric distention and belching. Can cause metabolic alkalosis. Na -fluid retention
Calcium carbonate (Tums, os-cal): less soluble. Reacts with HCL to form CO2 and CaCl2. Belching and metabolic alkalosis. Milk-alkali syndrome (hypercalcemia, renal insufficiency, metabolic alkalosis)
Excessive doses of both of these can result in hypercalcemia, renal insufficiency.
Magnesium Hydroxide/ Aluminum Hydroxide: With HCL it forms magnesium chloride or aluminum chloride and water. No gas is made, no belching. met alkalosis is uncommon. Can cause osmotic diarrhea so given with Maalox. Dont give these long term to patients with renal insufficiency.
From ppt (Magnesium Hyrdroxide-osmotic diarrhea; Aluminum Hydroxide- constipation)
Adverse: diarrhea, constipation, acid-base balance, milk-alkali syndrome. All of these affect the absorption of other meds by binding the drug, so don’t give within two hours of tetracyclines, fluoroquinolones, itraconazole, and iron
Proton Pump Inhibitors
Omeprazole, esomeprazole, lansoprazole, rabeprazole, pantoprazole
Esomeprazole and pantoprazole are also IV
MOA: All are lipophilic weak bases that become protonated in the parietal cell canaliculus (active form) and forms a thiophilic sulfenamide cation, which forms a disulfide bond with the H/K ATPase, irreversibly inactivating it.
pharmacokinetics: Ideal: short serum half life, activated near site of action, long duration of action. Omeprazole is available as powder formulation that containes sodium bicarb. Administered as inactive prodrugs. capsule dissolves in alkaline intestine. Omeprazole has fastest onset of action. 50% bioavail. 3-4 days of usage before full inactivation of enzyme. Rapid first-pass metabolism
In contrast to H2 blockers, they inhibit both fasting and meal stimulated secretion.
Uses: GERD- most effective agent in this disease, and Peptic Ulcer Disease- heals more than 90% of duodenal ulcers within 4 weeks and gastric ulcers in 6-8 weeks, NSAID ulcers, gastrinoma
*H. pylori: heal the ulcer and kill the organism. 2 antibiotics and a proton pump inhibitor
Adverse: very safe. low B12 levels, respiratory and enteric infections (C. difficile), increased gastrin (no acidic feedback inh)
CI: decreased acid alters absorption of ketoconazole, itraconazole, digoxin, atazanavir.
H2-receptor antagonists
Use has declined since proton pump inhibitors were made
Cimetidine, ranitidine, famotidine, nizatidine
Cimetidine, ranitidine, famotidine: all undergo first pass metabolism- 50% bioavailability. serum half life of 1.1-4 hrs. In elderly, decline of 50% drug clearance
MOA: competitive inhibition at parietal cell H2 receptor and suppress acid secretion in linear dose dep manner. Highly selective. Reduces acid secretion stimulated by histamine, gastrin, and cholinomimetic agents through 2 mech:
1) Histamine released from ECL cells by gastrin or vagal is blocked.
2) with H2 blockade, gastrin and vagal stimulation on parietal cells is less effective.
Especially effective at inhibition of nocturnal acid secretion
Treatment of GERD, peptic ulcer disease (Usesless in H. pylori associated ulcers), nonulcer dyspepsia, prevention of bleeding from stress-related gastritis
Adverse: cimetidine is associated with mental status change and can cause gynecomastia or impotence. Don’t use in pregnancy. Can cause blood dyscrasias
CI: cimetidine interferes with CYP. No interactions with nizatidine and famotidine.
Sucralfate
viscous tenacious paste that binds to ulcers or erosions for 6 hours.
less than 3% of drug is absorbed, the rest is eliminated in feces.
Used in critically ill to prevent stress ulcers
MOA: negative charge sucrose sulfate binds to positive charged proteins in the base of ulcer
Adverse: constipationi in 2% due to aluminum salt
Misoprostol
Prostaglandin analog of PGE1
oral absorption, then metabolized to a free acid. less than 30 min half life
acid inhibitory and mucosal protective properties. Stimulates bicarb and enhances blood flow at mucosa. Binds to PG receptor on parietal cells, reducing histamine stimulated cAMP production causing acid inh.
Uses: peptic ulcers from NSAIDS and termination of pregnancies in conjunction with mifepristone
Adverse: diarrhea and cramping, uterine contractions so dont use in pregnancy
Latanoprost
Topically active PGF2alpha derivative used for treatment of open angle glaucoma
Prostacyclin
AKA: PGI2, epoprostenol
Synthesized by the vascular endothelium and is a powerful vasodilator and inhibitor of platelet aggregation.
Used clinically to treat pulmonary hypertension and portopulmonary hypertension